Advertisement

International Journal of Clinical Oncology

, Volume 24, Issue 6, pp 677–685 | Cite as

Optimal treatment strategy for rectal cancer based on the risk factors for recurrence patterns

  • Takehito Yamamoto
  • Kenji KawadaEmail author
  • Koya Hida
  • Riki Ganeko
  • Susumu Inamoto
  • Mami Yoshitomi
  • Takeshi Watanabe
  • Yoshiharu Sakai
Original Article

Abstract

Background

For rectal cancer, multimodality therapeutic approach is necessary to prevent local recurrence and distant metastasis. However, the efficacy of additional treatments, such as neoadjuvant chemoradiotherapy (nCRT), neoadjuvant chemotherapy (NAC), and lateral pelvic lymph node dissection (LPLND), has not been scrutinized.

Methods

Recurrence patterns were categorized into local recurrence and distant metastasis. Local recurrence was classified into two types: (1) pelvic cavity recurrence and (2) LPLN recurrence. First, we analyzed the risk factors for each recurrence pattern. Second, based on the status of clinically suspected involvement of circumferential resection margin (cCRM), the efficacy of additional treatments was investigated.

Results

A total of 240 patients was enrolled. nCRT was performed for 25 (10%), NAC was for 46 (19%), and LPLND was for 35 patients (15%). As the recurrence patterns, pelvic cavity recurrence occurred in 15 (6%), LPLN recurrence in 8 (3%), and distant metastasis in 42 patients (18%). Five-year overall survival and relapse-free survival were 87% and 70%, respectively. Multivariate analysis indicated that pelvic cavity recurrence was associated with cCRM status and tumor histology, that LPLN recurrence was with serum carcinoembryonic antigen level and LPLN swelling, and that distant metastasis was with clinical N category. In the cCRM-positive subgroup (n = 66), cumulative rate of pelvic cavity recurrence was lower in the nCRT group than in the NAC or non-NAC/nCRT group (P = 0.02 and 0.09, respectively).

Conclusion

cCRM status was associated with pelvic cavity recurrence, and LPLN swelling was with LPLN recurrence. nCRT could reduce pelvic cavity recurrence in cCRM-positive subgroup.

Keywords

Rectal cancer Neoadjuvant chemoradiotherapy Neoadjuvant chemotherapy Lateral lymph node dissection Circumferential resection margin 

Notes

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341:457–460CrossRefGoogle Scholar
  2. 2.
    van Gijn W, Marijnen CA, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575–582CrossRefGoogle Scholar
  3. 3.
    Birgisson H, Pahlman L, Gunnarsson U et al (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:6126–6131CrossRefGoogle Scholar
  4. 4.
    Birgisson H, Pahlman L, Gunnarsson U et al (2007) Late adverse effects of radiation therapy for rectal cancer—a systematic overview. Acta Oncol 46:504–516CrossRefGoogle Scholar
  5. 5.
    Birgisson H, Pahlman L, Gunnarsson U et al (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23:8697–8705CrossRefGoogle Scholar
  6. 6.
    Fujita S, Akasu T, Mizusawa J et al (2012) Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol 13:616–621CrossRefGoogle Scholar
  7. 7.
    Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847–1858CrossRefGoogle Scholar
  8. 8.
    Yamaguchi T, Konishi T, Kinugasa Y et al (2017) Laparoscopic versus open lateral lymph node dissection for locally advanced low rectal cancer: a subgroup analysis of a large multicenter cohort study in Japan. Dis Colon Rectum 60:954–964CrossRefGoogle Scholar
  9. 9.
    Moriya Y, Hojo K, Sawada T et al (1989) Significance of lateral node dissection for advanced rectal carcinoma at or below the peritoneal reflection. Dis Colon Rectum 32:307–315CrossRefGoogle Scholar
  10. 10.
    Hojo K, Koyama Y, Moriya Y (1982) Lymphatic spread and its prognostic value in patients with rectal cancer. Am J Surg 144:350–354CrossRefGoogle Scholar
  11. 11.
    Watanabe T, Itabashi M, Shimada Y et al (2015) Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 20:207–239CrossRefGoogle Scholar
  12. 12.
    Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926–1933CrossRefGoogle Scholar
  13. 13.
    Glynne-Jones R, Wyrwicz L, Tiret E et al (2017) Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv22–iv40CrossRefGoogle Scholar
  14. 14.
    Benson AB 3rd, Venook AP, Bekaii-Saab T et al (2015) Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw 13:719–728 (quiz 728) Google Scholar
  15. 15.
    Hasegawa S, Takahashi R, Hida K et al (2016) Revisiting the treatment strategy for rectal cancer through the pattern of local recurrence. Eur J Surg Oncol 42:1674–1679CrossRefGoogle Scholar
  16. 16.
    Enriquez-Navascues JM, Borda N, Lizerazu A et al (2011) Patterns of local recurrence in rectal cancer after a multidisciplinary approach. World J Gastroenterol 17:1674–1684CrossRefGoogle Scholar
  17. 17.
    Kusters M, Marijnen CA, van de Velde CJ et al (2010) Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol 36:470–476CrossRefGoogle Scholar
  18. 18.
    Kim TH, Jeong SY, Choi DH et al (2008) Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol 15:729–737CrossRefGoogle Scholar
  19. 19.
    Japanese classification of Colorectal Carcinoma (2009) English 2nd edition. Kanehara, TokyoGoogle Scholar
  20. 20.
    Patel UB, Taylor F, Blomqvist L et al (2011) Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 29:3753–3760CrossRefGoogle Scholar
  21. 21.
    Taylor FG, Quirke P, Heald RJ et al (2011) One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. Br J Surg 98:872–879CrossRefGoogle Scholar
  22. 22.
    Sato T, Kokuba Y, Koizumi W et al (2007) Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 69:1442–1447CrossRefGoogle Scholar
  23. 23.
    Choi HJ, Kim NK, Keum KC et al (2008) Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. Radiother Oncol 87:361–366CrossRefGoogle Scholar
  24. 24.
    Sato T, Hayakawa K, Tomita N et al (2016) A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1). Radiother Oncol 120:222–227CrossRefGoogle Scholar
  25. 25.
    Ishihara S, Kawai K, Tanaka T et al (2017) Oncological outcomes of lateral pelvic lymph node metastasis in rectal cancer treated with preoperative chemoradiotherapy. Dis Colon Rectum 60:469–476CrossRefGoogle Scholar
  26. 26.
    Takahashi T, Ueno M, Azekura K et al (2000) Lateral node dissection and total mesorectal excision for rectal cancer. Dis Colon Rectum 43:S59–S68CrossRefGoogle Scholar
  27. 27.
    Moriya Y, Sugihara K, Akasu T et al (1997) Importance of extended lymphadenectomy with lateral node dissection for advanced lower rectal cancer. World J Surg 21:728–732CrossRefGoogle Scholar
  28. 28.
    Sugihara K, Moriya Y, Akasu T et al (1996) Pelvic autonomic nerve preservation for patients with rectal carcinoma. Oncologic and functional outcome. Cancer 78:1871–1880CrossRefGoogle Scholar
  29. 29.
    Ueno M, Oya M, Azekura K et al (2005) Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. Br J Surg 92:756–763CrossRefGoogle Scholar
  30. 30.
    Fujita S, Mizusawa J, Kanemitsu Y et al (2017) Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial. Ann Surg 266:201–207CrossRefGoogle Scholar
  31. 31.
    Oh HK, Kang SB, Lee SM et al (2014) Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study. Ann Surg Oncol 21:2280–2287CrossRefGoogle Scholar
  32. 32.
    Kim MJ, Kim TH, Kim DY et al (2015) Can chemoradiation allow for omission of lateral pelvic node dissection for locally advanced rectal cancer? J Surg Oncol 111:459–464CrossRefGoogle Scholar
  33. 33.
    Akiyoshi T, Matsueda K, Hiratsuka M et al (2015) Indications for lateral pelvic lymph node dissection based on magnetic resonance imaging before and after preoperative chemoradiotherapy in patients with advanced low-rectal cancer. Ann Surg Oncol 22(Suppl 3):S614–S620CrossRefGoogle Scholar
  34. 34.
    Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15:184–190CrossRefGoogle Scholar
  35. 35.
    Akasu T, Iinuma G, Takawa M et al (2009) Accuracy of high-resolution magnetic resonance imaging in preoperative staging of rectal cancer. Ann Surg Oncol 16:2787–2794CrossRefGoogle Scholar
  36. 36.
    Fujita S, Yamamoto S, Akasu T et al (2009) Risk factors of lateral pelvic lymph node metastasis in advanced rectal cancer. Int J Colorectal Dis 24:1085–1090CrossRefGoogle Scholar
  37. 37.
    Ogawa S, Hida J, Ike H et al (2016) Selection of lymph node-positive cases based on perirectal and lateral pelvic lymph nodes using magnetic resonance imaging: study of the Japanese society for cancer of the colon and rectum. Ann Surg Oncol 23:1187–1194CrossRefGoogle Scholar
  38. 38.
    Taylor FG, Quirke P, Heald RJ et al (2011) Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 253:711–719CrossRefGoogle Scholar
  39. 39.
    Glimelius B, Tiret E, Cervantes A et al (2013) Group EGW, rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi81–88CrossRefGoogle Scholar
  40. 40.
    Sao Juliao GP, Habr-Gama A, Vailati BB et al (2017) The good, the bad and the ugly: rectal cancers in the twenty-first century. Tech Coloproctol 21:573–575CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.Department of Surgery, Graduate School of MedicineKyoto UniversityKyotoJapan

Personalised recommendations